Harbin Medisan Pharmaceutical Co., Ltd (SHE: 002900) has announced a significant patent and technology transfer agreement with China Pharmaceutical University (CPU) for the development rights of a peroxisome proliferator-activated receptor (PPAR) agonist. This agreement involves an upfront payment of RMB 11 million (USD 1.6 million) and potential milestone payments totaling RMB 120 million (USD 17.3 million), in addition to net sales-based royalties.
PPAR Agonist Development and Applications
The PPAR agonist, currently in the pre-clinical stage, is under development for the treatment of primary biliary cholangitis (PBS) and non-alcoholic steatohepatitis (NASH), along with other immune and metabolic diseases. PPAR agonists are known for their role in regulating cellular differentiation, development, and metabolism, making them promising candidates for treating a range of conditions.
Strategic Investment in Innovation
This agreement signifies Medisan’s strategic investment in innovative drug development, particularly in the area of immune and metabolic disease treatments. The collaboration with CPU is expected to leverage the academic institution’s research capabilities and Medisan’s pharmaceutical development expertise to advance the PPAR agonist towards clinical trials and, ultimately, market availability.-Fineline Info & Tech
